KOKOMO, Ind., Dec. 01, 2016 -- Haynes International, Inc. (NASDAQ:HAYN), a leading developer, manufacturer and marketer of technologically advanced high performance alloys, is pleased to announce the development of HAYNES® 233™ alloy. This alloy is expected to have excellent oxidation resistance coupled with superior creep strength at temperatures up to 2100°F (or higher) - a combination of properties never before achieved in a readily fabricated alloy. The alloy achieves its exceptional oxidation resistance through the formation of a protective alumina layer, while the high creep strength is a result of solid-solution and carbide strengthening. Additionally, for use in intermediate temperature applications the alloy can be age-hardened by heat treatment to produce even greater strength. Finally, the alloy can be readily fabricated exhibiting very good hot workability, cold formability and weldability. Potential uses include applications in the aerospace and industrial gas turbine, industrial heating, and emerging technology markets. Material is expected to be available for trial evaluation as manufacturing progresses. Planned product forms include sheet, plate, billet, bar, wire, pipe, and tube.
About Haynes International
Haynes International, Inc. is a leading developer, manufacturer and marketer of technologically advanced, nickel and cobalt-based high-performance alloys, primarily for use in the aerospace, chemical processing and industrial gas turbine industries.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this press release are forward-looking. In many cases, you can identify forward-looking statements by terminology, such as “may”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of various factors, many of which are beyond the Company's control.
The Company has based these forward-looking statements on its current expectations and projections about future events. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based upon those assumptions also could be incorrect. Risks and uncertainties, some of which are discussed in Item 1A. of Part 1 to the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016, may affect the accuracy of forward-looking statements.
The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Ron Block Manager – Market and Business Development Haynes International, Inc. 765-456-6170


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Samsung Electronics Shares Jump on HBM4 Mass Production Report
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



